Jim Simons
CNTA

Jim Simons’s Centessa Pharmaceuticals CNTA Stock Holding History

Jim Simons’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.35M Sell
185,000
-94,300
-34% -$2.41M 0.01% 1150
2025
Q4 		$6.99M Buy
279,300
+114,700
+70% +$2.91M 0.01% 1110
2025
Q3 		$3.99M Sell
164,600
-220,300
-57% -$3.92M 0.01% 1629
2025
Q2 		$5.06M Buy
384,900
+206,900
+116% +$2.62M 0.01% 1522
2025
Q1 		$2.56M Sell
178,000
-600
-0.3% -$9.82K ﹤0.01% 1847
2024
Q4 		$2.99M Sell
178,600
-31,000
-15% -$514K ﹤0.01% 1780
2024
Q3 		$3.35M Buy
209,600
+35,900
+21% +$440K 0.01% 1699
2024
Q2 		$1.57M Sell
173,700
-45,100
-21% -$428K ﹤0.01% 2028
2024
Q1 		$2.47M Buy
218,800
+33,200
+18% +$314K ﹤0.01% 1891
2023
Q4 		$1.48M Buy
185,600
+132,500
+250% +$888K ﹤0.01% 2147
2023
Q3 		$344K Buy
53,100
+18,800
+55% +$129K ﹤0.01% 2869
2023
Q2 		$212K Buy
34,300
+18,600
+118% +$88.2K ﹤0.01% 3281
2023
Q1 		$60K Buy
+15,700
New +$57.4K ﹤0.01% 3616

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jim Simons's CNTA Position: Q1 2026 in Review

Jim Simons reduced its Centessa Pharmaceuticals (CNTA) stake by 34% in Q1 2026, selling an estimated $2.41M and leaving 185,000 shares worth $7.35M. The position accounts for 0.01% of the portfolio, ranked #1150.

Jim Simons first reported a position in CNTA in Q1 2023 and has held it in 13 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Jim Simons held 185,000 shares of Centessa Pharmaceuticals worth $7.35M as of Q1 2026.
  • Jim Simons sold 94,300 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2.41M.
  • Centessa Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1150 holding.
  • Jim Simons first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.